Symbols / OPK $1.16 -2.52%
OPK Chart
About
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 890.53M |
| Enterprise Value | 935.66M | Income | -225.68M | Sales | 606.88M |
| Book/sh | 1.67 | Cash/sh | 0.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2275 | IPO | — |
| P/E | — | Forward P/E | -3.52 | PEG | — |
| P/S | 1.47 | P/B | 0.69 | P/C | — |
| EV/EBITDA | -7.35 | EV/Sales | 1.54 | Quick Ratio | 3.21 |
| Current Ratio | 3.97 | Debt/Eq | 31.29 | LT Debt/Eq | — |
| EPS (ttm) | -0.29 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | -19.20% | Earnings | 2026-04-30 | ROA | -6.62% |
| ROE | -17.14% | ROIC | — | Gross Margin | 13.50% |
| Oper. Margin | -28.98% | Profit Margin | -37.19% | Shs Outstand | 759.07M |
| Shs Float | 339.36M | Short Float | 7.20% | Short Ratio | 9.75 |
| Short Interest | — | 52W High | 1.87 | 52W Low | 1.11 |
| Beta | 1.52 | Avg Volume | 3.17M | Volume | 1.65M |
| Target Price | $3.40 | Recom | Buy | Prev Close | $1.19 |
| Price | $1.16 | Change | -2.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.40
Mean price target
2. Current target
$1.16
Latest analyst target
3. DCF / Fair value
$-3.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.16
Low
$1.40
High
$8.50
Mean
$3.40
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-11-20 | init | JP Morgan | — → Neutral | — |
| 2025-10-31 | down | Jefferies | Buy → Hold | $2 |
| 2025-10-30 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-05-01 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-04-25 | init | JP Morgan | — → Neutral | — |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-28 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-20 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-17 | reit | Piper Sandler | Overweight → Overweight | $3 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-07-18 | main | Piper Sandler | Overweight → Overweight | $3 |
News
RSS: Latest OPK news- OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands - Yahoo Finance Fri, 01 Aug 2025 07
- Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - The Globe and Mail Wed, 18 Feb 2026 08
- OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up - simplywall.st Fri, 19 Sep 2025 07
- Opko Health CEO Phillip Frost buys $737,747 in OPK stock - Investing.com ue, 18 Nov 2025 08
- Insider Purchase: CEO & Chairman of $OPK Buys 155,496 Shares - Quiver Quantitative Wed, 19 Nov 2025 08
- OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. hu, 31 Jul 2025 07
- OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts - Nasdaq Fri, 27 Feb 2026 17
- OPKO Health (NASDAQ: OPK) in Regeneron deal: $7M upfront, up to $200M per molecule - Stock Titan Wed, 29 Oct 2025 07
- OPKO Health (NASDAQ:OPK) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat Sat, 07 Mar 2026 09
- Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Yahoo Finance ue, 17 Feb 2026 08
- OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. Wed, 30 Apr 2025 07
- OPKO HEALTH Earnings Results: $OPK Reports Quarterly Earnings - Quiver Quantitative Wed, 29 Oct 2025 07
- A Look At OPKO Health (OPK) Valuation As Shares Trade Around US$1.30 - simplywall.st hu, 15 Jan 2026 08
- OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat Fri, 20 Feb 2026 08
- OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 580000 | 768807 | — | Purchase at price 1.30 - 1.34 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-11-21 00:00:00 | I |
| 1 | 580000 | 771328 | — | Purchase at price 1.32 - 1.35 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-20 00:00:00 | I |
| 2 | 580000 | 759115 | — | Purchase at price 1.28 - 1.32 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-11-19 00:00:00 | I |
| 3 | 533300 | 678906 | — | Purchase at price 1.24 - 1.29 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-18 00:00:00 | I |
| 4 | 46700 | 58842 | — | Stock Award(Grant) at price 1.26 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-18 00:00:00 | I |
| 5 | 150000 | 213435 | — | Purchase at price 1.42 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-31 00:00:00 | I |
| 6 | 440000 | — | — | Stock Gift at price 0.00 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-18 00:00:00 | I |
| 7 | 675000 | 891000 | — | Purchase at price 1.32 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-08-08 00:00:00 | I |
| 8 | 125000 | 184650 | — | Purchase at price 1.48 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-08 00:00:00 | I |
| 9 | 100000 | 164850 | — | Purchase at price 1.65 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-04-01 00:00:00 | I |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 6.58M | 20.02M | 53.55K | 3.32M |
| TaxRateForCalcs | 0.07 | 0.21 | 0.21 | 0.16 |
| NormalizedEBITDA | -142.42M | 39.95M | -65.77M | -291.33M |
| TotalUnusualItems | 101.15M | 95.33M | 255.00K | 20.52M |
| TotalUnusualItemsExcludingGoodwill | 101.15M | 95.33M | 255.00K | 20.52M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -225.68M | -53.22M | -188.86M | -328.40M |
| ReconciledDepreciation | 91.63M | 98.18M | 105.30M | 108.66M |
| ReconciledCostOfRevenue | 387.20M | 479.09M | 526.10M | 695.11M |
| EBITDA | -41.27M | 135.28M | -65.52M | -270.81M |
| EBIT | -132.90M | 37.10M | -170.81M | -379.46M |
| NetInterestIncome | -93.65M | -39.04M | -9.52M | -10.07M |
| InterestExpense | 108.46M | 47.47M | 13.51M | 12.06M |
| InterestIncome | 14.81M | 8.43M | 3.98M | 1.98M |
| NormalizedIncome | -320.24M | -128.54M | -189.06M | -345.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -225.68M | -53.22M | -188.86M | -328.40M |
| TotalExpenses | 825.86M | 986.70M | 1.02B | 1.25B |
| TotalOperatingIncomeAsReported | -117.41M | -152.06M | -157.02M | -226.25M |
| DilutedAverageShares | 751.13M | 694.02M | 751.72M | 719.06M |
| BasicAverageShares | 751.13M | 694.02M | 751.72M | 719.06M |
| DilutedEPS | -0.30 | -0.08 | -0.25 | -0.46 |
| BasicEPS | -0.30 | -0.08 | -0.25 | -0.46 |
| DilutedNIAvailtoComStockholders | -225.68M | -53.22M | -188.86M | -328.40M |
| NetIncomeCommonStockholders | -225.68M | -53.22M | -188.86M | -328.40M |
| NetIncome | -225.68M | -53.22M | -188.86M | -328.40M |
| NetIncomeIncludingNoncontrollingInterests | -225.68M | -53.22M | -188.86M | -328.40M |
| NetIncomeContinuousOperations | -225.68M | -53.22M | -188.86M | -328.40M |
| EarningsFromEquityInterestNetOfTax | -29.00K | -18.00K | -107.00K | -383.00K |
| TaxProvision | -15.71M | 42.84M | 4.44M | -63.50M |
| PretaxIncome | -241.36M | -10.36M | -184.32M | -391.52M |
| OtherIncomeExpense | 71.27M | 302.24M | -16.74M | -135.32M |
| OtherNonOperatingIncomeExpenses | -29.88M | 206.90M | -16.99M | -155.84M |
| SpecialIncomeCharges | 101.58M | 121.49M | 1.04M | 19.87M |
| GainOnSaleOfPPE | 101.58M | 121.49M | 0.00 | 18.56M |
| WriteOff | 0.00 | |||
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | -1.04M | -1.31M |
| GainOnSaleOfSecurity | -429.00K | -26.16M | -781.00K | 649.00K |
| NetNonOperatingInterestIncomeExpense | -93.65M | -39.04M | -9.52M | -10.07M |
| InterestExpenseNonOperating | 108.46M | 47.47M | 13.51M | 12.06M |
| InterestIncomeNonOperating | 14.81M | 8.43M | 3.98M | 1.98M |
| OperatingIncome | -218.99M | -273.56M | -158.06M | -246.12M |
| OperatingExpense | 424.93M | 492.07M | 476.18M | 534.34M |
| DepreciationAmortizationDepletionIncomeStatement | 77.89M | 82.63M | 86.03M | 87.78M |
| DepreciationAndAmortizationInIncomeStatement | 77.89M | 82.63M | 86.03M | 87.78M |
| Amortization | 77.89M | 82.63M | 86.03M | 87.78M |
| AmortizationOfIntangiblesIncomeStatement | 77.89M | 82.63M | 86.03M | 87.78M |
| ResearchAndDevelopment | 124.03M | 105.21M | 89.59M | 73.89M |
| SellingGeneralAndAdministration | 223.00M | 304.22M | 300.56M | 372.67M |
| GrossProfit | 205.94M | 218.51M | 318.13M | 288.22M |
| CostOfRevenue | 400.94M | 494.63M | 545.37M | 715.98M |
| TotalRevenue | 606.88M | 713.14M | 863.50M | 1.00B |
| OperatingRevenue | 606.88M | 713.14M | 863.50M | 1.00B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 30.85M | 29.80M | 8.66M | 8.66M |
| OrdinarySharesNumber | 759.07M | 671.55M | 773.28M | 772.65M |
| ShareIssued | 789.92M | 701.35M | 781.94M | 781.31M |
| NetDebt | 5.27M | 153.45M | 102.87M | 70.14M |
| TotalDebt | 396.78M | 504.44M | 326.56M | 305.55M |
| TangibleBookValue | 72.39M | 24.58M | -144.32M | -52.72M |
| InvestedCapital | 1.61B | 1.80B | 1.64B | 1.82B |
| WorkingCapital | 435.20M | 468.99M | 109.42M | 181.04M |
| NetTangibleAssets | 72.39M | 24.58M | -144.32M | -52.72M |
| CapitalLeaseObligations | 52.82M | 67.24M | 77.24M | 49.49M |
| CommonStockEquity | 1.27B | 1.37B | 1.39B | 1.56B |
| TotalCapitalization | 1.60B | 1.79B | 1.61B | 1.78B |
| TotalEquityGrossMinorityInterest | 1.27B | 1.37B | 1.39B | 1.56B |
| StockholdersEquity | 1.27B | 1.37B | 1.39B | 1.56B |
| GainsLossesNotAffectingRetainedEarnings | -21.02M | -56.13M | -38.03M | -43.32M |
| OtherEquityAdjustments | -21.02M | -56.13M | -38.03M | -43.32M |
| TreasuryStock | 3.18M | 1.79M | 1.79M | 1.79M |
| RetainedEarnings | -2.29B | -2.07B | -2.01B | -1.82B |
| AdditionalPaidInCapital | 3.57B | 3.48B | 3.43B | 3.42B |
| CapitalStock | 7.90M | 7.01M | 7.82M | 7.81M |
| CommonStock | 7.90M | 7.01M | 7.82M | 7.81M |
| TotalLiabilitiesNetMinorityInterest | 663.99M | 834.76M | 622.48M | 605.61M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 517.31M | 641.67M | 422.43M | 392.13M |
| OtherNonCurrentLiabilities | 11.60M | 11.50M | 12.20M | 11.05M |
| EmployeeBenefits | 5.54M | 14.27M | 0.00 | |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 5.54M | 14.27M | 0.00 | |
| NonCurrentDeferredLiabilities | 126.24M | 140.80M | 126.78M | 126.56M |
| NonCurrentDeferredRevenue | 6.00K | 7.00K | 138.00K | 208.00K |
| NonCurrentDeferredTaxesLiabilities | 126.24M | 140.80M | 126.77M | 126.43M |
| LongTermDebtAndCapitalLeaseObligation | 373.92M | 475.10M | 283.45M | 254.52M |
| LongTermCapitalLeaseObligation | 40.21M | 52.91M | 61.41M | 35.05M |
| LongTermDebt | 333.71M | 422.18M | 222.03M | 219.47M |
| CurrentLiabilities | 146.68M | 193.10M | 200.05M | 213.48M |
| OtherCurrentLiabilities | 28.16M | |||
| CurrentDeferredLiabilities | 0.00 | 0.00 | 258.00K | |
| CurrentDeferredRevenue | 0.00 | 0.00 | 258.00K | |
| CurrentDebtAndCapitalLeaseObligation | 22.86M | 29.35M | 43.12M | 51.03M |
| CurrentCapitalLeaseObligation | 12.61M | 14.33M | 15.82M | 14.44M |
| CurrentDebt | 10.25M | 15.02M | 27.29M | 36.59M |
| OtherCurrentBorrowings | 10.25M | 15.02M | 27.29M | 36.59M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 33.78M | 34.17M | 28.95M | 33.77M |
| CurrentProvisions | 5.90M | 6.92M | 9.42M | 6.48M |
| PayablesAndAccruedExpenses | 84.14M | 122.66M | 118.56M | 122.21M |
| CurrentAccruedExpenses | 39.45M | 53.32M | 47.50M | 49.87M |
| InterestPayable | 5.44M | 8.31M | ||
| Payables | 44.70M | 69.35M | 71.06M | 72.34M |
| TotalTaxPayable | 3.60M | 22.27M | 1.38M | 5.35M |
| AccountsPayable | 41.10M | 47.07M | 69.68M | 66.99M |
| TotalAssets | 1.93B | 2.20B | 2.01B | 2.17B |
| TotalNonCurrentAssets | 1.35B | 1.54B | 1.70B | 1.77B |
| OtherNonCurrentAssets | 19.47M | 18.54M | 9.08M | 8.68M |
| FinancialAssets | 3.00K | 3.00K | 2.00K | 28.00K |
| InvestmentsAndAdvances | 14.16M | 54.58M | 16.08M | 28.05M |
| InvestmentinFinancialAssets | 13.41M | 53.79M | 5.50M | 6.03M |
| AvailableForSaleSecurities | 13.41M | 53.79M | 5.50M | 6.03M |
| LongTermEquityInvestment | 758.00K | 787.00K | 10.58M | 22.02M |
| GoodwillAndOtherIntangibleAssets | 1.20B | 1.34B | 1.53B | 1.61B |
| OtherIntangibleAssets | 711.28M | 811.61M | 935.28M | 1.02B |
| Goodwill | 484.29M | 529.25M | 598.26M | 595.85M |
| NetPPE | 120.86M | 124.14M | 143.52M | 121.60M |
| AccumulatedDepreciation | -125.62M | -138.70M | -157.13M | -142.41M |
| GrossPPE | 246.47M | 262.84M | 300.64M | 264.01M |
| Leases | 14.35M | 20.94M | 28.06M | 25.52M |
| ConstructionInProgress | 27.65M | 19.23M | 5.25M | 4.79M |
| OtherProperties | 46.93M | 54.00M | 68.09M | 38.73M |
| MachineryFurnitureEquipment | 139.44M | 153.36M | 177.93M | 174.34M |
| BuildingsAndImprovements | 15.57M | 13.06M | 18.89M | 18.31M |
| LandAndImprovements | 2.54M | 2.24M | 2.42M | 2.32M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 581.88M | 662.09M | 309.48M | 394.52M |
| OtherCurrentAssets | 8.17M | 10.71M | 7.67M | 6.25M |
| AssetsHeldForSaleCurrent | 0.00 | 314.99M | ||
| PrepaidAssets | 12.70M | 10.60M | 10.03M | 12.41M |
| Inventory | 65.82M | 56.80M | 65.70M | 74.06M |
| InventoriesAdjustmentsAllowances | -3.52M | -2.77M | -6.46M | -3.57M |
| FinishedGoods | 43.99M | 32.31M | 35.58M | 37.14M |
| WorkInProcess | 726.00K | 2.35M | 1.73M | 2.45M |
| RawMaterials | 24.62M | 24.91M | 34.84M | 38.05M |
| Receivables | 126.12M | 152.05M | 130.20M | 148.61M |
| OtherReceivables | 24.02M | 25.77M | 2.61M | 13.11M |
| TaxesReceivable | 11.84M | 8.27M | 4.21M | 8.19M |
| AccountsReceivable | 90.25M | 118.02M | 123.38M | 127.31M |
| AllowanceForDoubtfulAccountsReceivable | -2.07M | -1.27M | -2.00M | -4.16M |
| GrossAccountsReceivable | 92.33M | 119.28M | 125.38M | 131.47M |
| CashCashEquivalentsAndShortTermInvestments | 369.07M | 431.94M | 95.88M | 153.19M |
| CashAndCashEquivalents | 369.07M | 431.94M | 95.88M | 153.19M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -190.82M | -208.50M | -44.47M | -119.77M |
| RepurchaseOfCapitalStock | -47.04M | -90.22M | 0.00 | 0.00 |
| RepaymentOfDebt | -103.79M | -651.45M | -682.71M | -1.04B |
| IssuanceOfDebt | 33.03M | 939.43M | 671.68M | 1.06B |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -12.28M | -25.01M | -16.27M | -24.58M |
| InterestPaidSupplementalData | 37.94M | 20.88M | 8.13M | 7.42M |
| IncomeTaxPaidSupplementalData | 24.46M | 10.01M | 3.71M | 8.04M |
| EndCashPosition | 382.74M | 445.62M | 95.88M | 153.19M |
| BeginningCashPosition | 445.62M | 95.88M | 153.19M | 134.71M |
| EffectOfExchangeRateChanges | 3.43M | -3.16M | 388.00K | -339.00K |
| ChangesInCash | -66.30M | 352.89M | -57.70M | 18.82M |
| FinancingCashFlow | -118.06M | 184.17M | -11.30M | 22.97M |
| CashFlowFromContinuingFinancingActivities | -118.06M | 184.17M | -11.30M | 22.97M |
| NetOtherFinancingCharges | -13.38M | -188.00K | ||
| ProceedsFromStockOptionExercised | -256.00K | -208.00K | -272.00K | -774.00K |
| NetCommonStockIssuance | -47.04M | -90.22M | 0.00 | 0.00 |
| CommonStockPayments | -47.04M | -90.22M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | -70.76M | 287.98M | -11.03M | 23.75M |
| NetShortTermDebtIssuance | -11.24M | |||
| ShortTermDebtPayments | -1.70B | |||
| ShortTermDebtIssuance | 1.68B | |||
| NetLongTermDebtIssuance | -70.76M | 287.98M | -11.03M | 23.75M |
| LongTermDebtPayments | -103.79M | -651.45M | -682.71M | -1.04B |
| LongTermDebtIssuance | 33.03M | 939.43M | 671.68M | 1.06B |
| InvestingCashFlow | 230.30M | 352.21M | -18.20M | 91.04M |
| CashFlowFromContinuingInvestingActivities | 230.30M | 352.21M | -18.20M | 91.04M |
| NetInvestmentPurchaseAndSale | 52.18M | 166.60M | 364.00K | 115.42M |
| SaleOfInvestment | 52.18M | 166.60M | 364.00K | 115.42M |
| NetBusinessPurchaseAndSale | 190.10M | 210.38M | -5.00M | -1.76M |
| SaleOfBusiness | 197.77M | 210.38M | 0.00 | 0.00 |
| PurchaseOfBusiness | -7.67M | 0.00 | -5.00M | -1.76M |
| NetPPEPurchaseAndSale | 287.00K | 242.00K | 2.71M | 1.95M |
| SaleOfPPE | 287.00K | 242.00K | 2.71M | 1.95M |
| CapitalExpenditureReported | -12.28M | -25.01M | -16.27M | -24.58M |
| OperatingCashFlow | -178.54M | -183.49M | -28.20M | -95.19M |
| CashFlowFromContinuingOperatingActivities | -178.54M | -183.49M | -28.20M | -95.19M |
| ChangeInWorkingCapital | -41.18M | 32.17M | 21.80M | 42.65M |
| ChangeInOtherWorkingCapital | 178.00K | 3.90M | -1.04M | 2.37M |
| ChangeInOtherCurrentAssets | -5.40M | -3.74M | 6.88M | -1.48M |
| ChangeInPayablesAndAccruedExpense | -62.06M | 28.02M | -2.65M | -100.50M |
| ChangeInAccruedExpense | -47.84M | 48.68M | -5.48M | -91.11M |
| ChangeInPayable | -14.22M | -20.66M | 2.83M | -9.39M |
| ChangeInAccountPayable | -14.22M | -20.66M | 2.83M | -9.39M |
| ChangeInInventory | -4.12M | 4.22M | 15.20M | 13.66M |
| ChangeInReceivables | 30.21M | -220.00K | 3.41M | 128.60M |
| ChangesInAccountReceivables | 30.21M | -220.00K | 3.41M | 128.60M |
| OtherNonCashItems | 71.49M | 12.89M | 2.94M | 2.60M |
| StockBasedCompensation | 10.71M | 11.05M | 11.41M | 18.51M |
| UnrealizedGainLossOnInvestmentSecurities | 623.00K | -114.43M | 17.65M | 153.84M |
| AssetImpairmentCharge | 1.01M | 0.00 | 0.00 | 0.00 |
| DeferredTax | -15.00M | 14.74M | 146.00K | -74.41M |
| DeferredIncomeTax | -15.00M | 14.74M | 146.00K | -74.41M |
| DepreciationAmortizationDepletion | 91.63M | 98.18M | 105.30M | 108.66M |
| DepreciationAndAmortization | 91.63M | 98.18M | 105.30M | 108.66M |
| OperatingGainsLosses | -72.14M | -184.87M | 1.43M | -18.63M |
| EarningsLossesFromEquityInvestments | 29.00K | 18.00K | 107.00K | 383.00K |
| NetForeignCurrencyExchangeGainLoss | 2.35M | |||
| GainLossOnSaleOfPPE | -3.25M | -63.40M | 1.32M | -455.00K |
| GainLossOnSaleOfBusiness | 0.00 | -18.56M | 0.00 | |
| NetIncomeFromContinuingOperations | -225.68M | -53.22M | -188.86M | -328.40M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OPK
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|